The Bupivacaine Shortage in 2026: Where Things Stand

The Bupivacaine shortage that began in 2023 has stretched into its third year. For patients who rely on this critical local anesthetic for surgeries, epidurals, and pain procedures, the ongoing supply problems continue to cause delays, substitutions, and uncertainty.

Here's what you need to know right now — including whether the shortage is improving, how it affects your care, and what options are available.

Is Bupivacaine Still in Shortage?

Yes. As of early 2026, Bupivacaine injection remains on the FDA and ASHP drug shortage lists. Multiple formulations are affected:

• 0.75% preservative-free vials — the most severely affected, with back orders extending months
• 0.5% and 0.25% vials — intermittently available depending on manufacturer and region
• Bupivacaine with epinephrine — sporadic supply
• Marcaine Spinal (intrathecal formulation) — limited availability

Some concentrations have become easier to find in certain regions, but nationwide, the shortage is far from resolved.

Why Is Bupivacaine Still Hard to Find?

The same factors that triggered the shortage in 2023 continue to play out:

• Manufacturing challenges: Sterile injectable production is complex and slow to scale. Several manufacturers have faced quality control issues and production delays.
• Market concentration: Only a handful of companies produce generic Bupivacaine in the U.S., including Pfizer (Marcaine), Hospira, Fresenius Kabi, and Auromedics. When even one manufacturer goes offline, the impact is outsized.
• Discontinued products: Baxter's 2023 exit from certain Bupivacaine formulations permanently removed supply from the market.
• Increased demand: The volume of surgical procedures continues to grow, putting additional pressure on already-strained supply.

For a detailed look at the causes, read our article: Why Is Bupivacaine So Hard to Find?

How Much Does Bupivacaine Cost in 2026?

Bupivacaine is a generic injectable, so pricing depends on the formulation, concentration, and where you're purchasing it:

• Generic Bupivacaine 0.25% (50 mL vial): approximately $10 to $15
• Generic Bupivacaine 0.5% (50 mL vial): approximately $9 to $40
• Preservative-free formulations: $5 to $8 per 10 mL vial; higher for multi-packs
• Bupivacaine with epinephrine (50 mL vial): approximately $7 to $93
• Exparel (liposomal Bupivacaine): approximately $285 to $365 per vial

Because Bupivacaine is typically administered during a medical procedure, the cost is usually included in your facility or procedure bill — not purchased separately at a retail pharmacy. During shortages, however, some facilities may pass along higher acquisition costs.

For savings tips, check out our guide: How to Save Money on Bupivacaine.

What New Options Are Available?

Several developments have helped the situation since the shortage began:

FDA Temporary Importation

The FDA authorized the temporary importation of Bupivacaine Hydrochloride Injection from foreign manufacturers to help bridge supply gaps. These imported products meet safety standards but may look different from U.S.-marketed versions (different labeling, packaging, or ampule sizes).

Exparel as a Postsurgical Option

Exparel (liposomal Bupivacaine by Pacira BioSciences) provides up to 72 hours of pain relief from a single injection into the surgical site. While it doesn't replace standard Bupivacaine for epidurals or spinal blocks, it's become more widely adopted for postoperative pain management — especially in orthopedic, general, and colorectal surgeries.

Ropivacaine Substitution

Ropivacaine (Naropin) continues to be the most widely used substitute for Bupivacaine. It's in the same drug class, provides similar duration of anesthesia, and has a lower risk of cardiac toxicity. Learn more in our guide to Bupivacaine alternatives.

How to Find Bupivacaine in Stock

If you or your provider needs Bupivacaine, here are the most effective strategies:

1. Use Medfinder to check real-time availability at pharmacies and facilities near you.
2. Contact multiple distributors. Supply varies across McKesson, Cardinal Health, and AmerisourceBergen.
3. Try independent and compounding pharmacies. They may have access to supply that larger chains don't.
4. Ask about imported products. Your facility may be able to obtain FDA-authorized imported Bupivacaine.
5. Be flexible on concentration. If 0.75% isn't available, your provider may be able to work with 0.5% or 0.25%.

For a full breakdown of strategies, see our detailed guide: How to Find Bupivacaine in Stock Near You.

Final Thoughts

The Bupivacaine shortage is one of the most impactful drug supply disruptions affecting surgical care in the United States. While there are signs of gradual improvement — including FDA importation programs and growing use of alternatives — patients and providers will likely continue dealing with supply inconsistencies through 2026.

Stay informed, communicate with your healthcare team, and use tools like Medfinder to stay ahead of the shortage. Your care doesn't have to be compromised — but it does take a little more planning.